Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban

• Ping G. Tepper ,

  Roles Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing

  * E-mail: ping@pganalytics.com

  Affiliation Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

  http://orcid.org/0000-0001-7402-1662

  ⨯
• Jack Mardekian,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Outcomes & Evidence, Pfizer, Inc; New York, New York, United States of America

  ⨯
• Cristina Masseria,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Outcomes & Evidence, Pfizer, Inc; New York, New York, United States of America

  ⨯
• Hemant Phatak,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Global Health Economics and Outcomes Research, Bristol-Myers Squibb; Princeton, New Jersey, United States of America

  ⨯
• Shital Kamble,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Global Health Economics and Outcomes Research, Bristol-Myers Squibb; Princeton, New Jersey, United States of America

  ⨯
• Younos Abdulsattar,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Outcomes & Evidence, Pfizer, Inc; New York, New York, United States of America

  ⨯
• William Petkun,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Global Medical Affairs, Bristol-Myers Squibb; Princeton, New Jersey, United States of America

  ⨯
• Gregory Y. H. Lip

  Roles Conceptualization, Writing – original draft, Writing – review & editing

  Affiliation Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham, United Kingdom

  ⨯